- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
tim889 发表于 2022-12-15 05:34
我本人不爱国,也不恨国,只是恰好在中国的土地上呆了十几年。作为科学家(或者sicentist:更严谨的翻译是 ...
"(除了Lamivudine是英国的GSK研发的)" - 不对!
维基百科
Bernard Belleau 和 Paul Nguyen-Ba 在位于蒙特利尔的 IAF BioChem International, Inc. 实验室工作时,于 1988 年在麦吉尔大学工作期间发明了外消旋 BCH-189(负型称为拉米夫定),并于 1989 年分离出负对映异构体 . 样本首先被送到耶鲁大学的郑永基那里研究其毒性[15] 当与 AZT 联合使用时,他发现拉米夫定的阴性形式减少了副作用并提高了药物抑制逆转录酶的效率。 [16] 拉米夫定和 AZT 的组合提高了抑制 HIV 用来复制其遗传物质的酶的效率。 因此,拉米夫定被确定为比其他逆转录病毒药物对线粒体 DNA 毒性更小的药物。 [17][18]
拉米夫定于 1995 年 11 月 17 日获得食品和药物管理局 (FDA) 的批准,可与齐多夫定 (AZT) 一起使用,并于 2002 年再次批准作为每日一次给药的药物。 它在世界卫生组织的基本药物清单上。 [9]
Wikipedia
Racemic BCH-189 (the minus form is known as lamivudine) was invented by Bernard Belleau while at work at McGill University and Paul Nguyen-Ba at the Montreal-based IAF BioChem International, Inc. laboratories in 1988 and the minus enantiomer isolated in 1989. Samples were first sent to Yung-Chi Cheng of Yale University for study of its toxicity.[15] When used in combination with AZT, he discovered that lamivudine's negative form reduced side effects and increased the drug's efficiency at inhibiting reverse transcriptase.[16] The combination of lamivudine and AZT increased the efficiency at inhibiting an enzyme HIV uses to reproduce its genetic material. As a result, lamivudine was identified as a less toxic agent to mitochondria DNA than other retroviral drugs.[17][18]
Lamivudine was approved by the Food and Drug Administration (FDA) on November 17, 1995, for use with zidovudine (AZT) and again in 2002 as a once-a-day dosed medication. It is on the World Health Organization's List of Essential Medicines.[9] |
|